Navigation Links
PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
Date:10/23/2008

y and development strategy, Dr. Alberto Grignolo has helped numerous companies manage business risk by promoting effective regulatory strategies and relationships with regulators. Leading a global team of experts at PAREXEL Consulting, Dr. Grignolo oversees the management of regulatory submissions for clients with Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for progress in personalized drug development, and has helped the industry recognize emerging opportunities to deliver safe and effective medicines to the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation, and held management positions in regulatory affairs at Smith Kline & French Laboratories. He has served as an adviser to the Institute of Medicine of the National Academy of Sciences on human subject protection in clinical trials. He is currently a member of the Executive Committee of the Clinical Trials Transformation Initiative (CTTI). Dr. Grignolo has served as a leader of several industry organizations, including as Chairman of RAPS and on the Board of Directors for DIA. Dr. Grignolo holds a Ph.D. in Psychology from the University of North Carolina at Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral work in neuropharmacology at Duke University Medical Center. He is currently Adjunct Associate Professor at the Massachusetts College of Pharmacy and Health Sciences.

Good Clinical Practice Journal (GCPj) (http://www.gcpj.com) addresses the regulatory, strategic, and clinical issues that directly impact clinical studies globally.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
2. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
3. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
4. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
5. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
6. PAREXEL Closes the Acquisition of ClinPhone
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
9. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
11. PAREXEL Expands Global Clinical Logistics Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently ... The company has added a AS16 Sharples centrifuge to harvest products after fermentation. ... or fungal fermentation process development. , The new centrifuge greatly expands production ...
(Date:8/25/2015)... Doximity, the leading medical network for ... its second annual Residency Navigator , an ... of doctors research and compare residency training programs ... senior medical students used Doximity to research the ... The new Residency Navigator brings an unprecedented level ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... shares of Common Stock in Exchange, for Senior Subordinated and ... ... interest, SEATTLE, Feb. 13 Cell Therapeutics, Inc.,("CTI" or the ... in aggregate principal of its outstanding 5.75%,Convertible Senior Subordinated Notes due 2008 ...
... (Nasdaq:,CEPH) issued the following statement in response to ... Commission (FTC) in U.S. District Court for the,District ... entered,into by the company in late 2005 and ... infringement litigation and seeking to,permanently enjoin the Company ...
... Board Authority to Implement Reverse Stock Split and ... Shares and Authorized Shares, NEW HAVEN, Conn., Feb. 13 ... Special Meeting of,Stockholders was held at the Omni Hotel in ... meeting, shareholders voted to approve amendments to the,Company,s Restated Certificate ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 3Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... study of 60 beaches in Southern California suggests that ... highest levels when tides are ebbing during the new ... managers better assess the potential risk of swimming. , ... the American Chemical Society's journal Environmental Science & Technology. ...
... a healthy human gene to prevent blindness in mice ... strikes boys. , Writing in the August issue of ... how they successfully used gene therapy in mice to ... from mothers, who retain their sight, to their sons. ...
... a new laser therapy that destroys cancer cells but ... described in a study published in the Aug. 1 ... of Sciences (PNAS). , "One of the longstanding problems ... normal body tissue," says Hongjie Dai, an associate professor ...
Cached Biology News:Beach pollution is worst during new and full moon 2Gene therapy works in mice to prevent blindness that strikes boys 2Gene therapy works in mice to prevent blindness that strikes boys 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4
...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Biology Products: